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Abstract: Some individuals who are chronically infected with hep-
atitis B virus (HBV) eventually lose hepatitis B surface antigen (HBsAg).
Hepatocellular carcinoma (HCC) has been demonstrated to occur in a
few patients after loss of HBsAg. Neither factors associatedwith loss of
HBsAg nor the incidence of HCC thereafter have been clearly eluci-
dated. We performed a prospective population-based cohort study in
1271 Alaska native persons with chronic HBV infection followed for
an average of 19.6 years to determine factors associated with loss of
HBsAg and risk of developing HCC thereafter. HBsAg loss occurred in
158 persons for a rate of HBsAg clearance of 0.7%/year. Older age,
but not sex, was associatedwith clearance of HBsAg, and loss of HBsAg
was not associated with any particular HBV genotypes (A–D, and F)
found in this population. Participants were followed for an average
of 108.9 months after HBsAg loss. Six patients, two with cirrhosis
and four without, developed HCC a mean of 7.3 years after HBsAg
clearance (range, 2.0–15.5 years). The incidenceofHCCafter clearance
of HBsAgwas 36.8 per 100,000 per year (95% CI 13.5–80.0) which was
signiﬁcantly lower than the rate in those who remained HBsAg-posi-
tive (195.7 cases per 100,000 person-years of follow-up [95% CI
141.1–264.5; P < 0.001). After loss of HBsAg, HBV DNA was detected
in the sera of 28 (18%) of those who cleared amedian of 3.6 years after
clearance. Conclusion: HCC can occur in personswith chronic hepatitis
B who have lost HBsAg, even in the absence of cirrhosis. These persons
should still be followed with periodic liver ultrasound to detect HCC
early.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Journal of Hepatology 20
Keywords: HBV endemicity; Hepatitis B surface antigen loss; Prognostic factors;
Chronic inﬂammation; Cirrhosis; Hepatocellular carcinoma.
* Corresponding author. Address: Clinic of Gastroenterology, Department of
Medicine, Azienda Ospedaliero-Universitaria, Policlinico G.B. Rossi, Piazzale L.A.
Scuro n. 10, 37134 Verona, Italy. Tel.: +39 045 8124205.
E-mail address: giovanna.fattovich@univr.it (G. Fattovich).
 Authors have contributed equally to the paper.
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HBsAg,
hepatitis B surface antigen; HCV, hepatitis C virus; HDV, hepatitis Delta virus.end-stage liver disease and hepatocellular carcinoma (HCC)
worldwide. Spontaneous or therapy-induced hepatitis B surface
antigen (HBsAg) clearance, with or without anti-HBs seroconver-
sion, is considered a highly favorable event. However, its inci-
dence, the facilitating factors, and the long term outcome of HBV
carriers experiencing HBsAg seroclearance, are still ill deﬁned.
The article by Simonetti et al. [1] provides additional data on the
rate and determinants of spontaneous HBsAg loss and prognosis
after seroclearance in a population-based cohort study from the
endemic area of Alaska, and highlights important differences in
outcome between countries of low and high HBV endemicity.Are there differences in the incidence and determinants (age
at diagnosis, HBV genotypes) of spontaneous HBsAg clearance
between chronic HBV carriers from endemic and Western
regions?
The HBsAg seroclearance rate was thought to be lower in high as
compared to low HBV endemic countries; however, this was
likely due to insufﬁcient length of follow-up, the longest studies
in this setting being performed in Western countries [2,3]. Recent
data from Taiwan indicate that when prolonging the follow-up
length, the annual seroclearance rate is 1%, a ﬁgure similar to
Western studies [2–4]. A common predisposing factor was older
age at entry both in high and low HBV endemic regions [1,2,4],
although with approximately a decade of anticipation of the
age of entry in the only population-based study from the high
endemic area of Alaska [1] (Table 1). As the article by Simonetti
et al. [1] has shown, HBV genotypes (A–D, and F) are not associ-
ated with different rates of HBsAg seroclearance. Studies have
indicated that HBsAg seroclearance is consistently associated
with improvement in liver biochemistry and in liver histology
(when available) and favorable long term prognosis, provided
that HBsAg loss occurred at a younger age, in the absence of con-
current hepatitis C virus (HCV) or hepatitis delta virus (HDV)
infection, and before the development of cirrhosis. This leads to
the second, relevant question.Does the disease progression stop after HBsAg
seroconversion?
Disease progression such as HCC, decompensation or liver-related
death still occurs after HBsAg seroclearance, [1,6–11] (Table 1). In10 vol. 52 j 768–770
Table 1. Occurrence of hepatocellular carcinoma, decompensation and liver-related death/LT after HBsAg seroclearance in patients with chronic hepatitis B
infection according to clinical status and geographic area.
Author [reference] Geographic
area
No. HBs Ag+
pts/No. pts
clearing HBsAg
Mean
follow-up
(yrs)
Rate/yr
HBsAg
lossa (%)
Mean age at
entry/mean age
at HBsAg loss (yrs)
Clinical status
at HBsAg loss
Mean follow-up
after HBsAg
loss (yrs)
No.
HCC
No.
decompensation
No.
death/
LT
Simonetti [1] Alaska 1271/158 19.6 0.7 21/na Asymptomatic
carriers
8.6 6 (1) na na
Chu [4] Taiwan 1965/245 10.8 1.1 35/48 na na na na
Manno [2] Italy 296/59 29.1 1 36/52b 16b 0 0 0
Fattovich [3] Italy 70/18 25.3 1 29/52b Inactive
carriers
8.6b 0 0 0
Zacharakis [5] Greece 195/16 4.9 1.6 34/na na na na na
Chen [6] Taiwan na/189 na na na/43 5.1 2 (2) 0 1 (1)
Ahn [7] Korea 432c/32 18.5 0.6d na/50 Chronic
hepatitis
1.6 1 na na
Arase [8] Japan nae/164 4 nae na/51 6.5 0 0 0
Yuen [9] China na/285 9 na na/49 Chronic
hepatitis or
cirrhosis
3.0 7f 5 na
Fattovich [10] Europe 309/32 5.6 0.8 45/51b 4.6 1 (1) 2 2 (1)
Chen [6] Taiwan na/29 na na na/54 5.1 1 (1) 4 (2) 1 (1)
Ahn [7] Korea 432c/17 18.5 0.6d na/50 Cirrhosis 1.6 4 na na
Arase [8] Japan nae/67 4 nae na/51 6.5 2 0 0
Tong [11] United States nae/13 15 nae 41/54 na 4 na na
HCC, hepatocellular carcinoma; LT, liver transplantation; na, not available.
Number in parentheses refer to number of patients with concurrent hepatitis C virus or hepatitis delta virus infection.
a Patients receiving antiviral therapy were excluded from the analysis.
b Updated by the authors.
c The number of HBsAg-positive patients refers to the total study population including both subjects with chronic hepatitis and cirrhosis.
d The yearly rate of HBsAg loss was calculated for the total study population including both patients with chronic hepatitis and cirrhosis.
e Untreated patients cannot be disentangled.
f Six of the seven patients had cirrhosis at the time of HBsAg loss.
JOURNAL OF HEPATOLOGYAsianpatientswith cirrhosis,HCCdeveloped in3–23%of casesdur-
ing 1.6–6.5 years of follow-up after HBsAg clearance [6–8]. In a
recent study from the United States, 35 patients with chronic hep-
atitis B (71% of Asian origin) were followed for a median period of
15 years after HBsAg seroclearance, and HCC developed in 4 (30%)
out of 13 patients with cirrhosis at the time of the initial visit [11].
The only study, on compensated cirrhosis type B from Europe,
showed that 3%of Caucasianpatients developedHCCanddieddur-
ingamean follow-upof4.6 years (range0.4–8.7) afterHBsAgclear-
ance [10]; furthermore, the only patient with HBsAg loss who
developed HCC was an untreated HCV co-infected subject with
persistent biochemical activity, suggesting a relevant role for
HCV in the occurrence of cirrhosis and HCC [10].
On the other hand, data on the natural history of chronic HBV
infection in Caucasian patients show that HCC rarely occurs in the
absence of signiﬁcant liver disease [2,3]. Indeed in the 30-year
longitudinal study of 296 Italian inactive HBsAg carriers, none
of the 59 subjects who became HBsAg negative, developed HCC
or other liver-related morbidity, or mortality during a mean fol-
low-up of 16 years after HBsAg clearance [2]. In another 25-year
longitudinal study of Italian patients with chronic hepatitis B at
enrollment, 18 of the 40 patients who became inactive carriers
with sustained disease remission lost their HBsAg, and none of
them developed HCC or died from liver-related causes during
an average follow-up of 8.6 years after HBsAg loss [3].
Overall these data conﬁrm that worldwide liver cirrhosis rep-
resents the major known risk factor for HCC and can be consid-
ered a premalignant condition even after HBsAg loss. Moreover,
the reported higher risk of HCC in patients with HBsAg loss after
age of 50 may merely reﬂect the longer duration of infection and
disease of these speciﬁc patients [9,11]. The study by Simonetti
et al. [1] shows that the incidence of HCC after clearance of HBsAg
was signiﬁcantly lower than the rate in those who remainedJournal of Hepatology 201HBsAg-positive (0.36 versus 1.9 per 100 person/year, respec-
tively) but still remains considerably high. A possible explanation
for this apparent contradiction comes from the data by Yuen et al.
[9] showing that despite HBsAg seroclearance, HBV persists in the
liver at low replicative and transcriptional levels allowing contin-
uous liver inﬂammation, facilitating progression of disease,
although at slower pace, and ultimately occurrence of HCC. As
also indicated by the study of Simonetti et al. [1], the mere pres-
ence of chronic liver disease (4 out of 6 HCC cases showing
chronic inﬂammation not yet at the cirrhotic stage) represents
a potential risk for the development of HCC. Proof of concept
for this comes from the data on HBV vaccination [12] showing
that this not only decreased the prevalence of HBsAg in children
from geographic areas of high endemicity but also dramatically
reduced the incidence of HCC in this age group, thus providing
the evidence that HCC is avoidable, by preventing the sequence
of chronic HBV infection-chronic inﬂammation-liver ﬁbrosis
and eventually cirrhosis and cancer.References
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